4DMedical (ASX:4DX) Is Up 20.0% After Expanding Philips CT:VQ Distribution Agreement - What's Changed

• On 2 December 2025, 4DMedical announced a significant expansion of its distribution agreement with Koninklijke Philips for CT:VQ, the company’s FDA-cleared, non-contrast CT ventilation and perfusion imaging solution.
• This deeper alignment with a global imaging leader could accelerate CT:VQ’s clinical adoption by pairing 4DMedical’s technology with Philips’ established hospital footprint and sales channels.
• We’ll now examine how the expanded Philips distribution for CT:VQ reshapes 4DMedical’s investment narrative and future commercial potential.

The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

4DMedical Investment Narrative Recap

To own 4DMedical today, you need to believe its lung imaging software can convert early clinical traction into meaningful, recurring revenue before cash constraints bite. The expanded Philips CT:VQ distribution looks material for the key short term catalyst of U.S. adoption, but it does not remove the immediate risks around high cash burn, limited runway and dependence on future capital raising.

The September 2025 FDA clearance and CMS reimbursement for CT:VQ sit at the heart of this story, because they created the regulatory and payment foundation that the new Philips agreement now aims to commercialize. Together, they sharpen the contrast between 4DMedical’s growing clinical and partnership momentum and its still modest A$5.9 million revenue base and ongoing losses, which remain central to assessing execution risk.

However, against this progress, investors should still be aware that liquidity pressure and reliance on fresh capital could...

Read the full narrative on 4DMedical (it's free!)

4DMedical’s narrative projects A$48.5 million in revenue and A$17.4 million in earnings by 2028.

Uncover how 4DMedical's forecasts yield a A$2.22 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community span from A$0.19 to A$4.25, showing how far apart individual views can be. When you set that against 4DMedical’s high cash burn and short cash runway, it underlines why many investors will want to compare several perspectives before deciding how this Philips expansion could influence the company’s future performance.

Explore 10 other fair value estimates on 4DMedical - why the stock might be worth over 2x more than the current price!

Build Your Own 4DMedical Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your 4DMedical research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free 4DMedical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 4DMedical's overall financial health at a glance.

Searching For A Fresh Perspective?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Find companies with promising cash flow potential yet trading below their fair value.
• We've found 14 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com